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Abstract: Cuprizone, copper chelator, treatment of mouse is a toxic model of multiple sclerosis (MS) in which oligodendrocyte
death, demyelination and remyelination can be observed. Understanding T and B cell subset as well as their cytokines involved in MS
pathogenesis still requires further scrutiny to better understand immune component of MS. The study presented here, aimed to evaluate
relevant cytokines, lymphocytes, and gene expressions profiles during demyelination and remyelination in the cuprizone mouse model
of MS. Eighty male C57BL/6J mice fed with 0.2% cuprizone for eight weeks. Cuprizone has been removed from the diet in the following
eight weeks. Cuprizone treated and control mice sacrificed biweekly, and corpus callosum of the brain was investigated by staining.
Lymphocyte cells of mice analyzed by flow cytometry with CD3e, CD11b, CD19, CD80, CD86, CD4, CD25 and FOXP3 antibodies. IFNgamma, IL-1alpha, IL-2, IL-5, IL-6, IL-10, IL-17, TNF-alpha cytokines were analyzed in plasma samples. Neuregulin 1 (Nrg1), ciliary
neurotrophic factor (Cntf) and C-X-C chemokine receptor type 4 (Cxcr4) gene expressions in corpus callosum sections of the mice
brain were quantified. Histochemistry analysis showed that demyelination began at the fourth week of cuprizone administration and
total demyelination occurred at the twelfth week in chronic model. Remyelination occurred at the fourth week of following withdrawal
of cuprizone from diet. The level of mature and activated T cells, regulatory T cells, T helper cells and mature B cells increased
during demyelination and decreased when cuprizone removed from diet. Further, both type 1 and type 2 cytokines together with the
proinflammatory cytokines increased. The level of oligodendrocyte maturation and survival genes showed differential gene expression
in parallel to that of demyelination and remyelination. In conclusion, for the first-time, involvement of both cellular immune response
and antibody response as well as oligodendrocyte maturation and survival factors having role in demyelination and remyelination of
cuprizone mouse model of MS have been shown.
Key words: Cuprizone mouse model, multiple sclerosis, demyelination, cytokines, cellular immune response, oligodendrocyte
maturation

1. Introduction
Multiple sclerosis (MS) is an immune-mediated, neuroinflammatory, and neurodegenerative disease of the
central nervous system (CNS) with the morphological
hallmarks of inflammation, demyelination, and axonal loss
(Grigoriadis et al., 2004; Disanto et al., 2010; Lassmann
2013). Although more than a century has passed since the
identification of clinical and pathological characteristic of
MS, both the etiology and molecular pathogenesis of this
disease are not yet conclusively known. The clinical course
of MS is highly variable and includes several subtypes and
variants (Siva, 2006). Both pathological and immunological
studies suggest that different cellular pathways may be

active in different MS subtypes (Goldenberg, 2012; Hauser
et al., 2013; Avsar et al., 2015).
Several well-characterized experimental animal
models of MS have enhanced our understanding of
the pathophysiology, such as experimental allergic
encephalomyelitis (EAE), toxin-induced demyelination
models, and virus-induced models. Among these, EAE has
been one of the most frequently studied one, which mirrors
inflammatory activity and has helped to understand
therapeutic intervention strategies in MS (Robinson et
al., 2014). However, EAE model does not directly allow
us to explore parameters related to demyelination and
remyelination, which are key characteristics of the disease.
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On the other hand, cuprizone-induced mouse model is
commonly used to specifically analyze nonautoimmune
mediated demyelination and spontaneous remyelination
processes combined with therapeutic effects (Praet et al.,
2014).
Cuprizone, (bis–cyclohexanone-oxaldihydrazone)
a copper chelator, induces a consistent demyelination
of the corpus callosum (CC) to young adult mice, that
leads to changes at the cellular and molecular level
including oligodendrocyte death, microglial and astrocyte
reactivation macrophage accumulation, and T cell
differentiations involving T-helper and regulatory T cells
(Zhan et al., 2020). When cuprizone is applied for only
six weeks, neurodegeneration becomes acute and full
recovery is seen after being removed from the diet, while
it becomes chronic when administered up to twelve weeks
and remyelination is not observed even if it is removed
from the diet. Cuprizone-induced model reflects the
degeneration of oligodendrocytes rather than direct loss
of myelin sheet that provides another line of evidence on
the assumption that inflammatory demyelination may
not be the only process relating to MS pathogenesis (Acs
and Kalman 2012). Furthermore, this approach in the
acute model produces a possibility for an assessment of
remyelination. It enables to monitor the molecular and
cellular changes during the recovery processes.
Cuprizone model also provides opportunity to
investigate immune system interference during the
formation of demyelination and remyelination because
demyelination occurs before the activation of inflammation
elements like macrophages / microglia, astrocytes and
formation of oligodendrocyte progenitor cell as well,
mature oligodendrocytes (Mason et al., 2000; Matsushima
and Morell 2001). Therefore, cuprizone model is a still
good model to focus on more on the neurodegenerative
aspects of MS compared to other animal models of MS
(Hochstrasser et al., 2018).
In this study, we aimed to assess the effects of cuprizone
induction on the level of inflammatory cytokines, T and
B cell subsets during demyelination and remyelination
through the administration of cuprizone for 8 weeks and
further 8 weeks for the recovery. Furthermore, during 16
weeks of experiment, the transcript levels of Neuregulin
1 (Nrg1), Ciliary neurotrophic factor (Cntf) and C-X-C
chemokine receptor type 4 (Cxcr4) genes, which are
important in oligodendrocyte survival, maturation, and
migration were analyzed.
2. Materials and methods
2.1. Mice and cuprizone treatment
Eighty (48 test and 32 control group) C57BL/6J male
mice with age of 5 to 6 weeks were used. They were kept
together in groups of four mice in 20 cages in standard

mouse facility conditions. Experimental procedures were
started after two weeks of acclimatization. Experimental
group of mice was provided powder chow containing 0.2%
cuprizone (bis-cyclohexanone oxaldihydrazone, Sigma, St.
Louis, MO) for 8 weeks as previously described (Kanekiyo
et al., 2013). Mouse bait was prepared by mixing 100 g
of powder chow with 200 mg cuprizone to obtain 0.2%
cuprizone chow mixture; a total of 50 g chow was daily
provided for subject group, and excess chow was daily
replaced. Control group did not receive cuprizone and they
were kept in separate cages. The powder cuprizone was
mixed with into ground chow ad libidum in a bowl inside
their cages. Tap water was used; water and food levels
were checked and refreshed daily. Cuprizone was removed
from the diet at the 8th week. The number of animals
restricted considering both statistical requirements and
ethical issues; therefore, biweekly sacrification of 10 mice
(6 cuprizone fed and 4 control mice) were performed
for 16 weeks. Experiments were repeated twice. At the
first study, 3 subject and 2 control mice were sacrificed
for biweekly analysis. At the second study, additional 3
subject and 2 control mice were used. In total, 6 cuprizone
treated and 4 untreated (total of 10 mice) for each time
point were used. Sacrification was performed under deep
anesthesia. Blood sample was removed from the heart of
mice via open-heart surgery. All the blood was removed
and aliquoted for FACS analyses for both cell surface
markers, and plasma was obtained for the cytokine assays.
Total brain was removed and embedded into 10% formalin
for immunohistochemistry analyses.
All animal procedures were in accordance with the
ethical considerations and were approved by the İstanbul
University, Cerrahpaşa School of Medicine, Animal Care
And Use Committee.
2.2. Histochemistry and Staining
The paraffin embedded tissues were sectioned at 5 mm in
thickness from the corpus callosum according to the mouse
atlas by Sidman et al. (Sidman et al., 1971) For routine
histology, the sections were stained with hematoxylin and
eosin (H&E) and luxol fast blue periodic acid schiff (LFPPAS) for myelin sheet observation. Sections were placed
in 10 mM citrate buffer (pH = 6) and boiled for 5 min in
a microwave. Sections were subsequently incubated (30
min, 37°C) in a buffer containing 5% serum of the host
animal. Myelin Basic Protein (MBP) staining was done
to assess myelination score by using MBP antibody (12)
(Novus, NB600-717), primary antibody reagents were
incubated either at 37 °C for 2 h or overnight at 4 °C.
Sections were then washed and incubated for 30 min at
room temperature with the appropriate secondary Ab
conjugated with either Horse Radish Peroxidase (HRP)
or Streptavidin visualization. Slides were mounted with
Vectashield medium (Vector Laboratories) and visualized
by using a light microscope (Leica DMLe, Germany).
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Morphology of the tissue and cells were monitored
at 10X, 40X and 100X under immersion oil. In order to
evaluate the demyelination, three independent researchers
observed the slides in a double-blind fashion. Sections were
semi quantitatively scored from zero to three as described
by Lindner and colleagues (Lindner, et al. 2008). Zero
indicated the total demyelination, and three indicated the
normal myelination of brain section with no myelin loss.
Subsequently, score one indicates the myelination of 1/3,
score two; 2/3 of myelin fibers.
2.3. Flow cytometry analyses
Single-cell suspensions of peripheral blood mononuclear
cells (PBMC) were prepared, followed by lysis of Red
Blood Cells (RBC) in 0.83% NH4Cl. Cells were first treated
with PBS supplemented with 5% FCS (Fetal Calf Serum).
Nonspecific antibody binding was prevented by using 1mg
per sample of Fc blocker (BD, Mouse Fc Block, Cat No:
553142) was used by 20 min of incubation. Antibodies
against CD3e (17A2), CD11b (M1/70), CD19 (1D3),
CD45 (30-F11), CD80 (B7-1, 16-10A1), CD83 (Michel17),
CD86 (GL1), CD4 (GK1.5), CD25 (PC61.5) conjugated
antibodies (eBioscience) were used for cell surface staining
and FOXP3 (JFK-16s) were used for intracellular staining
of activated T cells. Cells were fixed and permeabilized by
using eBioscienc Foxp3 / Transcription Factor Fixation/
Permeabilization concentrate and diluent (E Bioscience,
Cat No:00-5521) according to manufacturer’s protocol.
First cell pellet including a million cells was incubated with
conjugated antibody solution for 15 min at dark and room
temperature. Then pellet was washed by centrifugation
at 800g for 5 min twice. Then resuspended cell solution
was read at FACSCalibur (Becton Dickinson Biosciences).
A total of 10,000 events were analyzed for each sample.
The lymphocyte gate was defined by forward and side
scatters. Antibodies were observed by FITC, PE, and APC
channels. (Supplementary Figure). Data were analyzed
with CellQuest Software (Becton Dickinson Biosciences).
For cytokine assay, Mouse Th1/Th2 10plex kit
(eBioscience, BMS820FF), which is a bead-based analyte
detection system, was used with the plasma of mice blood.
Assay contains type 1 cytokines, including IL-2, IFNgamma, IL-12, TNF-beta, and type 2 cytokines including
IL-4, IL-5, IL-6, IL-10 and IL-13. Different set of 2 beads
sized with 4mm and 5mm are coated with antibodies
reacting with corresponding cytokines. Then each analyte
to be measured was incubated either with standards or
samples. A biotin- conjugated second antibody binding
to first antibody attached to the microbeads was used.
Streptavidin – Phycoerythrin was added, and the level of
cytokines was measured.
2.4. Quantitative real time PCR (qPCR)
Corpus callosum (cc) region of the brain was removed
according to mouse brain atlas description (Sidman, et
al. 1971). RNA was isolated from the cc by RNA isolation
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kit (Roche High Pure RNA Tissue Kit), and 1mg of RNA
obtained. mRNA was converted to complementary DNA
(cDNA) by using revert aid first strand cDNA synthesis
kit (Roche). Primers for Cxcr4, Cntf and Nrg1 target genes
and reference gene Gapdh1 were listed in Supplementary
Table. Gene expression levels were calculated by delta delta
Ct method.
2.5. Statistical analysis
Data were evaluated using unpaired Student’s t-test for
histochemistry results, analysis of variance (ANOVA)
for FACS and qPCR analysis and expressed as mean ±
standard deviation. Myelin scores were compared by
using multiple t test comparisons. Statistical analysis
was performed using the GraphPrism program package,
version 8 (GraphPad Software, San Diego, CA, USA).
3. Results
3.1. Eight-week cuprizone administration induced
chronic, partly reversible demyelination
Degree of demyelination in brain was evaluated in the CC
by LFB-PAS and MBP immune - stained sections. Based on
the LFB-PAS stained CC sections, degree of demyelination
was scored regarding the dissemination of CC integrity.
Semiquantitative scoring of LFB-PAS staining showed
that demyelination was maximum (2.3 ± 0.4) at 8. week
for the cuprizone fed mice, whereas control mice showed
no demyelination. Following the removal of cuprizone
from the diet at the 8th week, mice showed remyelination,
starting from the 14th week to the 16th week, showing
better amelioration each week. Anti-MBP staining showed
the level of MBP density at the CC sections. The level of
MBP staining was parallel with that of demyelination. The
level of anti-MBP staining was 1.2 ± 0.5 at 8th week and
2.6 ± 0. 4 at 1th week, indicating the remyelination after
the cuprizone removal from the diet (Figure 1).
3.2. T and B cells subsets levels increased during
demyelination and decreased after cuprizone treatment
The level of CD4 positive (CD4+) T and/or T helper cells
increased to 61 ± 3.5% at 8th week of cuprizone treatment
and decreased to 30 ± 4.4% at 16th week, whereas control
mice did not show significant change (p < 0.05) (Figure
2a). Antiinflammatory regulatory T cell level (Treg cells),
as indicated by CD4 + / CD25 + and FoxP3 + cells,
increased to 12.5±2.2 by the 10th week and decreased to
2.8 ± 1.2% at 14th week, whereas control mice did not
show significant change (p < 0.05) (Figure 2b). The level
of mature T cells in the immune system was assessed by
evaluation of CD3e (17A2) positive (CD3e+) cells. In
cuprizone-induced mice, the CD3e+ T cell level increased
to 78.4 ± 6.7% at 8th week and decreased thereafter with
the removal of cuprizone from diet (p < 0.05) (Figure 2c).
Macrophage antigen-1 (Mac-1), CD11b, positive cells
that shows the frequency of active macrophages, were
increased to 62.1 ± 4.3% by week 8 and then decreased to
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Figure 1. a) Histochemistry analysis showed the total
demyelination and remyelination in corpus callosum
section of the mice brain treated with 8 weeks of cuprizone
administration and following 8 weeks of withdrawal from
the diet. Scores indicated myelination score which is given
by two independent pathologists. 3: no effect on myelination,
+2: initial demyelination, +1: partial demyelination, +0: total
demyelination. Luxol Fast blue staining, MBP: Myelin basic
protein staining. Arrows indicate corpus callosum region. b)
Mean myelin scores of cuprizone treated and untreated groups.
Demyelination significantly differed at the 8th week (p = 0.001)
and 12th week of treatment (p = 0.02) c) Mean myelin scores
by using anti-MBP antibody staining of cuprizone treated and
untreated groups. Demyelination significantly differed at the 8th
week (p < 0.001) and the 12th week of the treatment (p = 0.008).
“Control” indicates mice group without cuprizone, and “Cup+”
indicates cuprizone treated mice group.
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42.4 ± 4.7% by week 16. Active macrophage cell frequency
significantly increased in response to cuprizone treatment
(p < 0.05), while control mice did not show significant
change (Figure 2d).
B cell involvement in the chronic demyelination model
significantly altered when compared to control mice. B
lymphocyte (CD19+) cell level decreased to 8.1 ± 2.6%
by week 8 and when cuprizone was withdrawn from the
diet, increased to 26.25 ± 5.5%, (p < 0.05), whereas control
mice did not show any significant change over 16 weeks
remained in average of 44.2 ± 2.8% (Figure 2e). On the
other hand, the activated / mature B lymphocyte (CD80/
CD86 + cells) and antigen presenting cell (CD83+ cell)
level increased to 31.0 ± 5.0% by the 8th week (Figure 2f)
and 25.0 ± 5.0% by the 6th week (Figure 2g), respectively,
in response to cuprizone (p < 0.05). Investigation on
leukocyte levels showed that T helper and T regulatory cell
levels increased during demyelination and decreased after
cuprizone was removed from the diet. B cell markers and
costimulatory B cells showed the B cell response during
the demyelination period.
3.3. Cuprizone treatment induced expression of various
inflammatory cells and cytokines as immune response
Eight weeks of cuprizone treatment leading to
demyelination triggered alterations in the level of various
pro- and anti-inflammatory cytokines at different times,
indicating a hypothetical sequence of immune cell
recruitment and activation. T helper and T regulatory
cell levels secreting pro- and anti-inflammatory cytokines
increased during demyelination and decreased after
cuprizone withdrawal from the diet. Type I cytokines
IFN-gamma and IL-2 significantly increased in response
to cuprizone treatment indicating cytokine based immune
response. IFN-gamma level increased to 30.0 ± 4.2% at the
6th and 8th week of cuprizone treatment and decreased
to 25.5 ± 3.9 over 16 weeks (p < 0.05) (Figure 3a). IL-2
increased to 5.2 ± 0.4% in subject group, whereas it did
not significantly change in controls (p = 0.0022) (Figure
3b). Type 2 cytokines IL-5, IL-6 Il-10 and TNF-alpha
significantly changed between week 8 to week 14. IL-5 (50.6
± 2.9%, p < 0.0001) and IL-6 (12.0 ± 1.5%, p < 0.0001) were
maximum at week 12 (Figure 3c, 3d). IL-10 was maximum
(37.4 ± 1.8%, p = 0.0069) at week 10 (Figure 3e), and TNFalpha was maximum (43.5 ± 3.5, p < 0.0001) at week 14
(Figure 3f). Proinflammatory cytokines IL-1alpha (8.1 ±
1.3, p < 0.0001), and IL-17 (36.2 ± 3.1, p < 0.0001) levels
were maximum at week 12 and significantly differed from
that of control mice (Figure 3g and 3h).
Cytokine analysis showed that the level of
proinflammatory cytokines was increased as initial
response to cuprizone treatment during demyelination
period, whereas antiinflammatory cytokines’ level
increased thereafter at the late stage of chronic
demyelination. Involvement of both Th1 and Th2 cytokines
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at different weeks of cuprizone treatment indicated
that complex interaction of various inflammatory cells
and cytokines were increased as immune response to
cuprizone. However, further studies are required on both
cellular and functional studies.
3.4. Cuprizone treatment affected the oligodendrocyte
maturation and survival associated gene expression
Neuregulin 1 (Nrg1) is epidermal growth factor family
protein and necessary for development of oligodendrocytes
(Mei and Xiong 2008). The level of Nrg1 gene expression
decreased significantly as an initial response to cuprizone
treatment between week 0 and week 4 and remained the
same between weeks 4 and 12 until the cuprizone was
removed, then increased to baseline, while the control
group showed no significant difference for 16 weeks (p <
0.001) (Figure 4a). Ciliary neurotrophic factor (Cntf) is
a survival factor for both neurons and oligodendrocytes
(Stankoff et al., 2002). Cntf expression decreased between
week 0 and week 4, then remained the same until week
8, but it then increased to a maximum by week 12 and
decreased immediately (p < 0.001) (Figure 4b). C-X-C
chemokine receptor type 4 (Cxcr4) is a chemokine
that is essential for the mobilization of hematopoietic
cells and oligodendrocytes. Cxcr4 expression showed
dramatic changes between the 4th and 12th weeks. Cxcr4
level increased by week 6 and then gradually decreased
and remained the same through week 12 (p < 0.001)
(Figure 4c). All gene expression results indicated chronic
demyelination pattern, which dramatic expression level
changes occurred between the 4th and 12th weeks.
4. Discussion
Cuprizone treatment of mice induces a highly reproducible
and consistent demyelination of distinct brain regions,
such as the corpus callosum (CC), which represents the
most frequently investigated white matter part in this
animal model (Hochstrasser et al., 2018; Zhan et al.,
2020). Five to six weeks of cuprizone treatment induces
almost completely demyelinated CC, which leads to acute
demyelination. When cuprizone is removed from the diet
in the weeks following acute demyelination, spontaneous
remyelination follows. In contrast, when the use of
cuprizone is extended (12 weeks or longer), remyelination
is severely restricted and chronic demyelination develops.
In the late stages of acute demyelination, spontaneous
remyelination partially occurs but fails under an ongoing
cuprizone treatment. (Skripuletz et al., 2008; Torkildsen
et al., 2008). In this study, eight weeks of 0.3% cuprizone
treatment triggered chronic demyelination in CC, and only
partial remyelination was achieved with the withdrawal of
cuprizone from the diet.
MS previously considered as Th1-mediated
autoimmune disease (Jadidi‐Niaragh and Mirshafiey,
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2011; Lassmann and Ransohoff, 2004). This concept was
developed based on MS pathological and immunological
studies obtained from both human samples and the
experimental autoimmune encephalomyelitis (EAE)
model. However, more recently a wide variety of
inconsistent data with the CD4-Th1 driven hypothesis has
emerged and supported the idea that other immunological
mechanisms including IL-23 cytokines and Th-17 cells, as
well as neurodegenerative components within the target
tissue may also contribute to the initiation, spread, and
modification of disease (Jadidi‐Niaragh and Mirshafiey,
2011). Current evidence on CD4 + autoreactive T cells
supports this concept as a central factor for the autoimmune
pathogenesis of MS (Sospedra and Martin, 2005). The
cuprizone model allows us to analyze the levels of these
cell types and their cytokines independently of the CD4
+ T cell-based immunological induction of MS. In this
study, eight weeks of cuprizone treatment increased the
level of CD4 + T helper cells until cuprizone was removed
from the diet and decreased immediately. However, the
level of regulatory T (Treg) cells (CD4 + / CD25 + / FoxP3)
increased significantly until week 12 of the experiment.
Treg cells are naturally occurring suppressor cells that
can prevent reactivity to both self and nonself antigens.
They can both enhance and suppress the activity of T
cells (Lee, 2018). In this study, the levels of Treg cells were
increased by week 12 in response to cuprizone treatment,
then decreased by week 16. Although cuprizone was
removed from the diet after 8 weeks; the level of regulatory
T cells increased over the next 4 weeks. This may be the
result of an increased immune response that is regulated
and suppressed by Treg cells. Results of Treg studies in
MS patients are conflicting. The level of FoxP3 protein
and mRNA in CD4+/CD25+ T cells decreased in MS
patients compared to healthy controls (Fritzsching et al.,
2011). However, there are other studies indicating the
decreased or aberrantly changed regulatory T cell levels
in MS patients (Venken et al., 2008; Viglietta et al., 2004).
Regarding the conflicting results in the patient studies and
the cuprizone model, we say that the role of Treg cells in
MS pathogenesis changes depending on the dynamic and
varying nature of the disease. In addition, cuprizone model
is only a model of MS showing the partial characteristics
of the disease on mice. It may not be reflecting the T cell
profile of disease on mice.
The level of CD3e + cells that function to
activate cytotoxic T cells and helper T cells increased
significantly at 8 weeks, decreased slightly 10 weeks
after the removal of the cuprizone and then significantly
decreased. CD3e results showed consistency with
Treg and CD4+ T cell levels. CD11b is known as
macrophage-1 antigen (Mac-1) and expressed on various
types of leukocytes including monocytes, granulocytes, and
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cytokines gated, and X-axis indicates the weeks. Six subjects, four control mice were used for each week.
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Figure 4. Gene expression analysis for oligodendrocyte
maturation and survival factors. Data were obtained from mRNA
of total corpus callosum (cc) homogenate. Y-axis indicates
relative gene expression by means of delta delta Ct analysis with
regard to GAPDH gene level. X-axis indicates the weeks. Three
subjects, two control mice were used for each week. “Control”
indicates mice group without cuprizone, and “Cup+” indicates
cuprizone treated mice group.

652

macrophages. CD11b+ cell level increased significantly at
the 6th and 8th weeks of cuprizone treatment. The level of
CD3e + and CD11b + cells in the blood indicates the onset
of an acute inflammation at the 6th week of treatment
followed by an increase in the level of T helper and Treg
cells and suppressing active inflammation.
The role of B cells in MS is diverse as both antibody
secreting plasma cells and antibody producing cells. They
can act as both anti- and proinflammatory cells in MS
pathogenesis (Lehmann-Horn et al., 2013). In addition,
B cell activation markers within the CSF of MS patients
predict the conversion between clinical subtypes of MS
and are associated to clinical parameters (Disanto et al.,
2012). CD19 is a B cell lymphocyte antigen and expressed
in all B lineage cells (Rich, et al. 2012). Although many
studies showed increased B cell count in MS patients and
an increase in the EAE model, to our knowledge, studies
demonstrating the role of B cells in the cuprizone-induced
demyelination and remyelination model are limited. In
this study, the level of CD19+ cells significantly increased
in cuprizone treated mice. After cuprizone removal,
B cell level decreased. Furthermore, the level of CD80
and CD86 double positive cells, expressed on B cells,
antigen presenting cells, macrophages and dendritic cells,
increased in response to cuprizone treatment. CD80/
CD86+ cells indicate the induced Th1 cell responses via
binding CD28 on T cells. CD80/CD86 increase causes
activation, proliferation, and increase in T cell cytokine
secretion (Li et al., 2016). It was also shown that the level of
CD80/CD86 cells decreased in response to interferon β-1b
therapy (Jensen et al., 2010). CD83 level was measured to
assess antigen presenting cell activation (Li et al., 2019).
Dendritic cells are critically involved in initiating primary
immune response and T cell dependent antibodies
(Vinuesa et al., 2010). In the cuprizone model, the level
of CD83+ cells significantly increased at 6th week and
dramatically decreased thereafter. The results may show
that active inflammation in the cuprizone model starts at
earlier weeks with proliferation of helper T cells as well as
B cells and then regulated by Treg cells.
Cytokine profile in serum sample of mice correlated
with cell surface receptor analysis. IFN-Gamma which
is a pro-inflammatory cytokine secreted by activated T
lymphocytes, dramatically increased at the 4 week of
treatment and slightly decreased thereafter. Previous
study by Gao X. et al also indicated an elevated IFNgamma expression in response to cuprizone treatment
(Gao et al., 2000). Furthermore, they also showed that
low level IFN-gamma expressing transgenic mice did
not show extensive demyelination unlike the cuprizone
treated wild type model. IL-17, IL-1alpha and TNF-alpha
function as pro-inflammatory cytokines that responds
to the invasion of the immune system and production

AVŞAR et al. / Turk J Biol
of inflammation. In cuprizone model, the level of IL-17
and IL1-alpha increased after 12 weeks of experiment,
whereas TNF-alpha increased at 14th week. Cytokine
analysis showed that the level of pro-inflammatory
cytokines increased as a response to cuprizone diet during
demyelination period, but reached the maximum level at
different weeks, showing a cascade of expression, whereas
antiinflammatory cytokines’ level increased later at the
second stage of chronic demyelination. IL-10 and IL-6
are the antiinflammatory cytokines that down regulates
the expression of Th1 cytokines. As expected during
remyelination, the level of IL-10 and IL-6 are significantly
differed compared to control mice.
Nrg1 (Neuregulin 1), Cntf (Ciliary Neurotophic
Factor), Cxcr4 (C-X-C Chemokine Receptor 4) gene
expressions were analyzed in this study as they play
important roles in oligodendrocyte survival, maturation
and oligodendrocyte precursor cell migration to the
demyelination site. In particular, Cxcr4 is an important
receptor for the chemokine Cxcl12, and the binding
of Cxcr4-Cxcl12 is important for oligodendrocyte
progenitor cell migration in the brain. Cxcr4 is expressed
by hematopoietic stem cells and Cxcl12 is expressed by
astrocytes and microglia in demyelination site. Previous
studies show that Cxcl12 expression levels decrease with
cuprizone treatment (Li et al., 2012; Sanadgol et al., 2017).
Nrg1 and Cntf are important factors for oligodendrocyte
maturation and survival (Stankoff et al., 2002; Taveggia et
al., 2008). Cntf is a polypeptide hormone, which affect the
central nervous system. Cntf is expressed by neurons and
microglia in CNS. Cntf injection to develop rat optic nerve
increases cell survival by 80%. Nrg1 is a protein and have 6
alternative splicing form. Nrg1 is expressed on neurons’ cell
surface and bind to ErbB receptors on oligodendrocytes.
Nrg1 promote the oligodendrocyte survival through ErbB
receptors on oligodendrocytes (Newbern and Birchmeier,
2010). However, Nrg1 is not an essential factor for central
nervous system myelination. Nrg1 knock-out mice central
nervous system can be myelinated (Velanac et al., 2012).
Nrg1 is an essential factor for Schwann cell survival.
Schwann cells are myelin cells in peripheral nervous
system. Therefore, Nrg1 is an important and essential
factor for peripheral nervous system myelination. If gene
expression changes of Nrg1 and Cntf in the cuprizone
model can be detected, their role in remyelination and how
they cause chronic demyelination can be demonstrated,
so that new treatments for MS and alternative strategies
for remyelination can be developed. Our results indicated
that, Nrg1 gene expression significantly decreases after 4
weeks of cuprizone treatment (p < 0.001), but it almost
did not change in 4th–12th weeks period (4th–10th week
p < 0.001). After 12 weeks, Nrg1 expression increased to
baseline with the removal of cuprizone from the diet. Cntf

decreased within the first 4 weeks of cuprizone treatment (p
< 0.05) but increased in 8–12 weeks of cuprizone treatment
(6th–8th weeks and p < 0.05, 8–10 weeks and p < 0.001).
After 12 weeks, Cntf expression increased to baseline
with the removal of cuprizone from the diet. Similarly,
Cxcr4 expression decreased by the 4th week (p <0.05) and
reached its maximum level at 6th week (p < 0.05). It then
decreased over a 6 to 12 week period (p <0.005), reaching
a minimum at week 12. At the 12th week, cuprizone was
removed from the feed, and the expression level of Cxcr4
increased to baseline after 4 weeks (p < 0.001). Only Cntf
gene expression level decreased after the 12th week, Nrg1,
Cxcr4 level increase after the 12th week. Cxcr4 expression
change pattern correlate with acute demyelination to
chronic demyelination transition. Cxcr4, Cntf, Nrg1 gene
expressions turn into the initial level after the withdrawal of
cuprizone from the chow. Although three gene expressions
change upon cuprizone treatment, solely is not sufficient
to claim that oligodendrocyte maturation and survival is
changed; it was only hypothesized that oligodendrocyte
cell death and further survival/maturation changes in
MS pathogenesis may be associated with the Cxcr4, Cntf
and Nrg1 gene expressions. However, further studies with
detailed cellular and functional analysis are required.
In conclusion, we provide new evidences that the
expression profile of surface receptors and cytokine profile
of cuprizone treated mice for 8 week showed similarity of
MS disease course. Th1 dependent immune response and
B cell costimulation increased during the demyelination
and decreased during remyelination, which is the
following 8-week period after cuprizone removal. In light
of our results, further investigations addressing specific
questions on the mechanisms underlying the etiology
and pathogenesis of MS will be needed. The cascade
of proinflammatory and antiinflammatory cytokines
needed to be questioned. Such research should include
immunological markers, clinical as well as response to
therapeutic intervention parameters.
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Supplementary data
Supplementary Table. qPCR-primers.
Gene
Nrg1
Cntf
Cxcr4
Gapdh

Primer

5’-3’ Sequence

Forward CAGGAACTCAGCCACAAACA
Reverse

CCCAGTCGTGGATGTAGATGT

Forward TTGATTCCACAGGCACAAAA
Reverse

CCCTGCCTGACTCAGAGGT

Forward TGGAACCGATCAGTGTGAGT
Reverse

GGGCAGGAAGATCCTATTGA

Forward CATCACTGCCACCCAGAAGACTG
Reverse

ATGCCAGTGAGCTTCCCGTTCAG

Supplementary Figure. Representative flow cytometry images to show gating strategy used in flow cytometry analysis.

1

